Familial Hypercholesterolemia
Familial Hypercholesterolemia Market

Familial Hypercholesterolemia (FH) is a genetic and hereditary disorder that leads to an increased LDL (bad) cholesterol. The condition occurs at birth and can cause heart attacks at an early age.  


Familial Hypercholesterolemia is an autosomal-dominant disorder associated with mutations in the LDL receptor gene that increases plasma low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Patients with FH are characterized by a less LDL clearance from the circulation and a rise in LDL synthesis, with changes in homozygotes being more marked than in heterozygotes, consistent with a gene dosage effect.


Familial Hypercholesterolemia Epidemiological Segmentation 

The Epidemiological Segmentation of Familial Hypercholesterolemia in 7MM from 2017 to 2030 is segmented as:- 

  • Prevalent Population of Familial Hypercholesterolemia
  • Diagnosed Prevalent Population of Familial Hypercholesterolemia
  • Mutation-specific Diagnosed Prevalence of Familial Hypercholesterolemia
  • Diagnosed Prevalence of Coronary Heart Disease due to Familial Hypercholesterolemia


Familial Hypercholesterolemia Epidemiology 

  • The total diagnosed prevalent population of FH in the 7MM in 2017 was 965,405
  • The diagnosed prevalent population of FH in the United States in 2017 was 244,214
  • Familial Hypercholesterolemia affects both females and males equally


Familial Hypercholesterolemia Market

The market size of Familial Hypercholesterolemia in the 7MM in 2017 was 1,069.27 USD Million


Familial Hypercholesterolemia Market Drivers

  • Emerging potential therapies
  • Promising organizations


Familial Hypercholesterolemia Market Barriers

  • Late diagnosis
  • Differential diagnosis
  • Lack of homozygous FH (HoFH) Awareness


Familial Hypercholesterolemia Emerging Drugs

The emerging drugs of the Familial Hypercholesterolemia market are 

  • Evinacumab (REGN1500)
  • Inclisiran (ALN-PCSSC)
  • LIB003 + Evolocumab
  • Gemcabene
  • Resmetirom (MGL-3196)
  • ARO-ANG3

And many others.  

 

Familial Hypercholesterolemia Key Players

The key players in the Familial Hypercholesterolemia market are

  • Regeneron Pharmaceuticals
  • Novartis
  • LIB Therapeutics
  • NeuroBo Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Arrowhead Pharmaceuticals

And many others.